English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/86570
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorCampillo, Nuria E.-
dc.contributor.authorPáez, Juan A.-
dc.date.accessioned2013-11-13T11:53:19Z-
dc.date.available2013-11-13T11:53:19Z-
dc.date.issued2009-
dc.identifierdoi: 10.2174/138955709788167628-
dc.identifierissn: 1389-5575-
dc.identifier.citationMini reviews in medicinal chemistry 9: 539- 559 (2009)-
dc.identifier.urihttp://hdl.handle.net/10261/86570-
dc.description.abstractAlzheimer's disease is a chronic and progressive neurodegenerative disorder. The presence of functional cannabinoid CB2 receptors in central nervous system (CNS) has provoked that this receptor and its agonist ligands are now considered as promising pharmacological targets for neurological diseases. Herein, we review the evidences supporting the potential role of the ECS as a therapeutic target, focused on CB2 receptor and its ligands, for the treatment of Alzheimer's disease. © 2009 Bentham Science Publishers Ltd.-
dc.language.isoeng-
dc.publisherBentham Science Publishers-
dc.rightsclosedAccess-
dc.titleCannabinoid system in neurodegeneration: New perspectives in Alzheimer's disease-
dc.typeartículo-
dc.identifier.doihttp://dx.doi.org/10.2174/138955709788167628-
dc.date.updated2013-11-13T11:53:19Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.